California-based Artera, which offers an AI-based test to personalize treatment for prostate cancer patients, announces its launch alongside a $90 million investment.
Johnson & Johnson, TIME Ventures, Koch Disruptive Technologies, Coatue, Walden Catalyst Ventures, The Factory and Breyer Capital participated in the round alongside angel investors Amarjit Gill, Clarence So, Marc Benioff, Lip-Bu Tan, Dennis Wong, Andy Jacques, Jim Breyer, Jeff Dean, Chris Re, Steve Blank and Michael Driscoll.
WHAT THEYRE DOING
Artera’s AI-powered multimodal test for prostate cancer patients, dubbed the ArteraAI Prostate Test, helps predict potential therapy benefits and a patient’s prognosis by analyzing clinical data and patient biopsy images.
The company will use the funds to distribute its prostate cancer test and develop tests to help personalize treatment options for other types of cancers.
“Over the past 18 months, Artera’s AI-based approach to personalized cancer treatment has unlocked commercial and regulatory traction well ahead of genomic competitors,” said Stephen Cho, partner at Coatue, in a statement. communicated. “We are thrilled to support Artera as a pioneer in computational diagnostics for an important therapeutic area.”
MARKET OVERVIEW
According to the CDC, approximately 13 out of 100 American men will develop prostate cancer in their lifetime, and two out of three men will die of prostate cancer. African-American men and those with a family history are more likely to get prostate cancer than other men.
Another digital health company looking to improve outcomes for prostate cancer patients is Avenda Health, which offers clinical decision support software. The company received FDA 510(K) clearance in November for its iQuest tool, intended to be used alongside MRI and biopsy results to help doctors provide more accurate cancer treatment.
